--- title: Kardigan Eyes $350 Million IPO as Precision Cardiology Pipeline Advances Across Three Late-Stage Programs description: Cardiovascular-focused biotech seeks Nasdaq debut with multiple clinical catalysts expected in 2027 and more than $600 million in pro forma liquidity image: https://blog.ipoprophet.com/hubfs/Kardigan%20Thumbnail.png --- [Skip to content](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/kardigan-eyes-350-million-ipo-as-precision-cardiology-pipeline-advances-across-three-late-stage-programs#main-content) [![IPO_PROPHET_BLUE logo](https://blog.ipoprophet.com/hs-fs/hubfs/IPO_PROPHET_BLUE%20logo.png?width=2973&height=302&name=IPO_PROPHET_BLUE%20logo.png)](https://www.IPOProphet.com) - [Login](https://app.ipoprophet.com/login) Open main navigation Close main navigation - [Login](https://app.ipoprophet.com/login) [Subscribe to our Newsletter](https://share.hsforms.com/1xXldKrGiQBCbNmtOz6j4Jwq3cu4) [Go Back to Home](http://www.ipoprophet.com/) [Go Back to Blog](http://www.ipoprophet.com/blog) Jun 15, 2026 4:47:17 PM # Kardigan Eyes $350 Million IPO as Precision Cardiology Pipeline Advances Across Three Late-Stage Programs ![Picture of Eric Friedman](https://app.hubspot.com/settings/avatar/7a4cca62b5a89282b41a283a43efa80e) [Eric Friedman](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/author/eric-friedman) Share: [facebook-f icon](http://www.facebook.com/share.php?u=https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/kardigan-eyes-350-million-ipo-as-precision-cardiology-pipeline-advances-across-three-late-stage-programs) [linkedin-in icon](http://www.linkedin.com/shareArticle?mini=true&url=https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/kardigan-eyes-350-million-ipo-as-precision-cardiology-pipeline-advances-across-three-late-stage-programs) [Twitter icon](https://twitter.com/intent/tweet?url=https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/kardigan-eyes-350-million-ipo-as-precision-cardiology-pipeline-advances-across-three-late-stage-programs) [pinterest-p icon](http://pinterest.com/pin/create/link/?url=https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/kardigan-eyes-350-million-ipo-as-precision-cardiology-pipeline-advances-across-three-late-stage-programs) [envelope icon](mailto:?body=https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/kardigan-eyes-350-million-ipo-as-precision-cardiology-pipeline-advances-across-three-late-stage-programs) ![](https://blog.ipoprophet.com/hs-fs/hubfs/image-png-Jun-15-2026-08-32-51-0397-PM.png?width=436&height=111&name=image-png-Jun-15-2026-08-32-51-0397-PM.png) Kardigan, Inc. (**KARD**) has filed for an initial public offering of **23.33 million shares** at a price range of **$14.00 to $16.00 per share**, seeking to raise approximately **$350 million** at the midpoint. At the midpoint price of **$15.00 per share**, Kardigan would be valued at approximately **$1.3 billion** based on **87.67 million shares outstanding** following the offering. The company plans to list on the **Nasdaq Global Market** under the ticker **KARD**, with **J.P. Morgan, Jefferies, Leerink Partners, and TD Cowen** serving as lead underwriters. Kardigan is a clinical-stage biotechnology company focused on developing precision medicines for cardiovascular diseases where no approved therapies currently exist. The company is led by a management team that includes former MyoKardia executives and has assembled a portfolio of three clinical-stage cardiovascular programs targeting large unmet medical needs. Kardigan's strategy combines targeted therapeutics with its proprietary Prolaio platform, which leverages wearable sensors, real-world patient data, and AI-driven analytics to improve clinical trial design and execution. The company's lead candidate, **Danicamtiv**, is currently being evaluated in the KINSHIP-DCM Phase 2b/3 trial for genetic dilated cardiomyopathy. **Kardigan** is also advancing Ataciguat, a soluble guanylate cyclase activator in a Phase 2b trial for moderate calcific aortic valve stenosis, and **Tonlamarsen**, an antisense oligonucleotide in a Phase 2 trial for the management of acute severe hypertension following hospitalization. All three programs are expected to generate meaningful clinical data during the first half of 2027, creating multiple potential catalysts for investors. Kardigan's Prolaio platform represents an additional differentiator. The technology integrates wearable sensors with proprietary analytics to collect continuous physiologic data from patients outside traditional clinical settings. Management believes the platform can improve trial efficiency, enhance patient engagement, and support the development of novel digital clinical endpoints that may accelerate drug development. Financially, Kardigan remains firmly in investment mode as it advances its pipeline. The company reported a net loss of $191.9 million in 2025, compared with $88.7 million in 2024, driven primarily by increased research and development spending. During the first quarter of 2026, Kardigan reported a net loss of $56.1 million. As of March 31, 2026, the company held $81.5 million of cash and cash equivalents and $205.6 million of short-term investments, providing total liquidity of approximately $287.1 million. Following the IPO, pro forma cash and investments are expected to exceed $600 million, which management believes will fund operations into 2028. Cardiovascular disease remains the leading cause of death globally, yet innovation in the sector has historically lagged other therapeutic areas. Kardigan is attempting to address that gap through a precision medicine approach focused on targeting the underlying drivers of disease rather than treating symptoms alone. With three clinical-stage assets, multiple expected data readouts in 2027, and a well-capitalized balance sheet, Kardigan enters the public markets as one of the larger and more diversified biotechnology IPOs of 2026. *Kardigan, Inc. is expected to IPO on June 18th, 2026.  * *![Kardigan Placard](https://blog.ipoprophet.com/hs-fs/hubfs/Kardigan%20Placard.png?width=1526&height=1024&name=Kardigan%20Placard.png)*   [2026](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/tag/2026), [Kardigan, Inc.](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/tag/kardigan-inc) ## Related posts [![](https://blog.ipoprophet.com/hs-fs/hubfs/Clear%20Street%20Thumbnail.png?height=200&name=Clear%20Street%20Thumbnail.png)](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/clear-street-group-sets-terms-for-nasdaq-ipo-as-tech-enabled-prime-brokerage-platform-prepares-to-go-public) [IPOs](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/tag/ipos), [Nasdaq](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/tag/nasdaq), [2026](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/tag/2026), [Clear Street Group](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/tag/clear-street-group) ## [Clear Street Group Sets Terms for Nasdaq IPO as Tech-Enabled Prime Brokerage Platform Prepares to Go Public](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/clear-street-group-sets-terms-for-nasdaq-ipo-as-tech-enabled-prime-brokerage-platform-prepares-to-go-public) ![Picture of Eric Friedman](https://app.hubspot.com/settings/avatar/7a4cca62b5a89282b41a283a43efa80e) [Eric Friedman](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/author/eric-friedman) Feb 5, 2026 3:03:47 PM [Read more](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/clear-street-group-sets-terms-for-nasdaq-ipo-as-tech-enabled-prime-brokerage-platform-prepares-to-go-public) [![](https://blog.ipoprophet.com/hs-fs/hubfs/Alamar%20Thumbnail%202.png?height=200&name=Alamar%20Thumbnail%202.png)](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/alamar-biosciences-targets-150m-ipo-as-precision-proteomics-platform-scales-toward-diagnostics) [2026](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/tag/2026), [Alamar Biosciences](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/tag/alamar-biosciences) ## [Alamar Biosciences Targets ~$150M IPO as Precision Proteomics Platform Scales Toward Diagnostics](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/alamar-biosciences-targets-150m-ipo-as-precision-proteomics-platform-scales-toward-diagnostics) ![Picture of Eric Friedman](https://app.hubspot.com/settings/avatar/7a4cca62b5a89282b41a283a43efa80e) [Eric Friedman](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/author/eric-friedman) Apr 14, 2026 2:29:36 PM Alamar Biosciences, Inc. (“ALMR”) is seeking to raise approximately $150.0 million in its initial... [Read more](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/alamar-biosciences-targets-150m-ipo-as-precision-proteomics-platform-scales-toward-diagnostics) [![](https://blog.ipoprophet.com/hs-fs/hubfs/CopperTech%20Metals%20Thumbnail.png?height=200&name=CopperTech%20Metals%20Thumbnail.png)](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/coppertech-positions-for-ai-and-electrification-boom-in-400-million-ipo) [IPOs](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/tag/ipos), [2026](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/tag/2026), [CopperTech Metals](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/tag/coppertech-metals) ## [CopperTech Positions for AI and Electrification Boom in $400 Million IPO](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/coppertech-positions-for-ai-and-electrification-boom-in-400-million-ipo) ![Picture of Eric Friedman](https://app.hubspot.com/settings/avatar/7a4cca62b5a89282b41a283a43efa80e) [Eric Friedman](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/author/eric-friedman) Jun 25, 2026 1:37:05 PM [Read more](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/coppertech-positions-for-ai-and-electrification-boom-in-400-million-ipo) [linkedin-in icon](https://www.linkedin.com/company/ipo-prophet-software/) [X Twitter icon](https://www.x.com/ipoprophet) --- [![IPO_PROPHET_WHITE-2](https://blog.ipoprophet.com/hs-fs/hubfs/IPO_PROPHET_WHITE-2.png?width=800&height=250&name=IPO_PROPHET_WHITE-2.png "IPO_PROPHET_WHITE-2")](http://www.ipoprophet.com) NONE OF THE CONTENT PUBLISHED ON THE WEBSITE OR MOBILE APP CONSTITUTES A RECOMMENDATION, SOLICITATION, ENDORSEMENT, OR OFFER BY IPO PROPHET™ OR ITS AFFILIATES TO BUY OR SELL ANY SECURITIES, FUTURES, OPTIONS, OR OTHER FINANCIAL INSTRUMENTS, OR PROVIDE ANY INVESTMENT ADVICE OR SERVICE. Copyright © 2025 ```json { "@context" : "https://schema.org", "@type" : "BlogPosting", "author" : { "@type" : "Person", "name" : "Eric Friedman", "url" : "https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/author/eric-friedman" }, "dateModified" : "2026-06-15T20:47:17.793Z", "datePublished" : "2026-06-15T20:47:17.000Z", "headline" : "Kardigan Eyes $350 Million IPO as Precision Cardiology Pipeline Advances Across Three Late-Stage Programs", "image" : [ "https://blog.ipoprophet.com/hubfs/Kardigan%20Thumbnail.png" ], "mainEntityOfPage" : { "@id" : "https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/kardigan-eyes-350-million-ipo-as-precision-cardiology-pipeline-advances-across-three-late-stage-programs", "@type" : "WebPage" }, "publisher" : { "@type" : "Organization", "logo" : { "@type" : "ImageObject", "url" : "https://blog.ipoprophet.com/hubfs/IPO_PROPHET_BLUE%20logo-1.png" }, "name" : "ipoprophet.com" } } ```